Areva Pharmaceuticals would like to announce the addition of Irinotecan HCL Injection 300mg/15ml to our existing Irinotecan family that includes 40mg/2ml and 100mg/5ml.
Areva Pharmaceuticals is excited to announce three new products to our ever-expanding portfolio:
Areva Pharmaceuticals Announces the Launch Temozolomide USP
Pamidronate Disodium now available.
Ernst & Young announces Areva Pharmaceuticals Founder & CEO Victor Swaminathan as an EY Entrepreneur Of The Year® 2015 Award finalist in Ohio Valley
Areva Pharmaceuticals was granted VAWD accreditation by NABP (National Association of Boards of Pharmacy)
Areva Pharmaceuticals was pleased to announce it was awarded contracts by Amerinet for Irinotecan and Pamidronate.
Areva Pharmaceuticals owners and community leaders were joined by residents of the Lanesville Indiana and outlying communities for a ribbon cutting ceremony and open house.
Areva Pharmaceuticals was awarded a contract with Apexus for Epirubicin, Irinotecan, and Pamidronate.
Local Community Rolls Out Red Carpet for Areva